severity lung disease cystic fibrosis related genetic propensity host produce tumor necrosis fector alpha polymorphism promoter region gene nucleotide NUMBER relative transcription start site important determing hosts response aim study assess correlation promoter polymorphism ex vivo production lipopolysaccharide lps stimulation clinical status fev1 weight bmi shwachman score incidence diabetes mellitus pseudomonas aeruginosa infection genotyping biallelic polymorphism performed using pcr cycler patients homozygous delta f NUMBER grouped according genotype tnf2 carriers n NUMBER median age NUMBER yr tnf1 homozygotes n NUMBER median age NUMBER yr measured using chemiluminescent immunometric assay trend higher values median tnf2 carriers vs tnf1 homozygotes x NUMBER vs NUMBER ns utest carrying polymorphism better lung function results fev1 NUMBER vs NUMBER ns differences equalized tnf2 carriers vs tnf1 NUMBER vs NUMBER ns fev1 NUMBER vs NUMBER ns age adjustment NUMBER yr n NUMBER median age tnf2 vs yr significant differences tnf values lps stimulation incidence diabetes mellitus promoter polymorphism does influence release blood cells clinical status tnf alpha tnf alpha tnf alpha tnf NUMBER tnf alpha z score tnf NUMBER real time tnf alpha tnf alpha mann whitney tnf1 tnf NUMBER tnf alpha female male NUMBER NUMBER female male NUMBER NUMBER pg ml pg ml NUMBER NUMBER